NCT00047333终止2 期
A Phase 2 Open-Label Study Of OSI-774 (NSC 718781) In Unresectable Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Progression-free survival
研究概览
简要总结
Phase II trial to study the effectiveness of erlotinib in treating patients who have liver cancer that cannot be surgically removed. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
详细描述
PRIMARY OBJECTIVES:
I. To assess progression-free survival (PFS) measured at 16 weeks following initiation of once daily continuous oral therapy with OSI-774 in patients with unresectable hepatocellular carcinoma.
SECONDARY OBJECTIVES:
I. To assess objective response rate, rate and duration of stable disease, time to progression, median and overall survival in this patient population, and any changes in tumor perfusion based on functional CT imaging.
II. To correlate response with patient characteristics including: age, disease stage (TNM, Okuda [6]), viral hepatitis status, pathologic grade of cirrhosis, Childs-Pugh status, Performance Status, serum values of: alpha feto-protein, bilirubin, transaminases, albumin; EGFR expression score by IHC; and development of skin rash during therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed hepatocellular carcinoma (HCC)not amenable to curative resection
- •No fibrolamellar HCC
- •No prior therapy for HCC, including systemic chemotherapy, hepatic arterial infusion of chemotherapeutic agents or irradiated microspheres, and epidermal growth factor receptor-targeting agents
- •The following prior therapies are allowed provided previously treated lesions remain separate from those to be evaluated in present study
- •Liver-directed therapy (e.g., radiofrequency ablation, transarterial embolization/chemoembolization, or percutaneous ethanol injection)
- •At least 1 unidimensionally measurable lesion
- •At least 20 mm by conventional techniques
- •Must have paraffin tissue block or unstained slides from biopsy or surgical specimen
- •No known brain metastases
- •No ascites that are refractory to conservative management (e.g., sodium restriction to 50 mEq/day dietary sodium and fluid restrictions and/or diuretics)
- •Performance status - ECOG 0-2
- •At least 16 weeks
- •Granulocyte count at least 1,500/mm^3
- •Platelet count at least 60,000/mm^3
- •Hemoglobin at least 10 g/dL
- •Bilirubin no greater than 1.8 mg/dL
- •Albumin at least 2.5 g/dL
- •AST/ALT no greater than 5 times upper limit of normal
- •PT no greater than 1-3 seconds over normal
- •No decompensated liver disease
- •No jaundice
- •No portosystemic encephalopathy (evidenced by confusion, asterixis, significant sleep disturbance, or hypothermia less than 36º Celsius)
- •No hyponatremia with sodium less than 125 mEq/L
- •No portal hypertension with bleeding esophageal or gastric varices within the past 3 months
- •Creatinine no greater than 2 mg/dL
- •No symptomatic congestive heart failure
- •No unstable angina pectoris
- •No cardiac arrhythmia
- •No gastrointestinal tract disease resulting in an inability to take oral medication or requirement for IV alimentation
- •No active peptic ulcer disease
- •No abnormalities of the cornea (e.g., dry eye syndrome or Sjögren's syndrome)
- •No congenital abnormality (e.g., Fuch's dystrophy)
- •No other uncontrolled concurrent illness that would preclude study participation
- •No ongoing or active infection
- •No psychiatric illness or social situation that would preclude study compliance
- •No other malignancy within the past 5 years except nonmelanoma skin cancer
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No prior surgical therapy affecting absorption
- •More than 30 days since prior investigational agents
- •No concurrent commercial or other investigational anticancer agents or therapies
- •No concurrent combination antiretroviral therapy for HIV-positive patients
排除标准
- 未提供
研究组 & 干预措施
Treatment (erlotinib hydrochloride)
Experimental
Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: erlotinib hydrochloride (Drug)
Treatment (erlotinib hydrochloride)
Experimental
Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
Treatment (erlotinib hydrochloride)
Experimental
Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: pharmacological study (Other)
结局指标
主要结局
Progression-free survival
时间窗: Time from initiation of therapy until documented disease progression, assessed at 16 weeks
Summarized by Kaplan-Meier curves, from which medians and progression-free survival can be attained.
次要结局
- Duration of stable disease(From the start of the treatment until the criteria for progression are met, assessed up to 4 years)
- Objective response rate(Up to 4 years)
- Rate of stable disease(Up to 4 years)
- Time to progression(Up to 4 years)
- Overall survival(Up to 4 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerAdult Primary Cholangiocellular CarcinomaAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00033462National Cancer Institute (NCI)78
终止
2 期
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT00459901Peter Kozuch13
已完成
1 期
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionAdult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Diffuse AstrocytomaAdult EpendymoblastomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult Myxopapillary EpendymomaAdult OligodendrogliomaAdult Pilocytic AstrocytomaAdult Primary Hepatocellular CarcinomaAdult SubependymomaAdvanced Adult Primary Liver CancerAdvanced Malignant MesotheliomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Adult Brain TumorRecurrent Adult Primary Liver CancerRecurrent Anal CancerRecurrent Basal Cell Carcinoma of the LipRecurrent Bladder CancerRecurrent Breast CancerRecurrent Cervical CancerRecurrent Colon CancerRecurrent Esophageal CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Malignant MesotheliomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Non-small Cell Lung CancerRecurrent Ovarian Epithelial CancerRecurrent Pancreatic CancerRecurrent Prostate CancerRecurrent Rectal CancerRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavityStage II Esophageal CancerStage II Pancreatic CancerStage III Esophageal CancerStage III Pancreatic CancerStage IIIB Non-small Cell Lung CancerStage IV Adenoid Cystic Carcinoma of the Oral CavityStage IV Anal CancerStage IV Basal Cell Carcinoma of the LipStage IV Bladder CancerStage IV Breast CancerStage IV Colon CancerStage IV Esophageal CancerStage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityStage IV Inverted Papilloma of the Paranasal Sinus and Nasal CavityStage IV Lymphoepithelioma of the NasopharynxStage IV Lymphoepithelioma of the OropharynxStage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityStage IV Mucoepidermoid Carcinoma of the Oral CavityStage IV Non-small Cell Lung CancerStage IV Ovarian Epithelial CancerStage IV Pancreatic CancerStage IV Prostate CancerStage IV Rectal CancerStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Verrucous Carcinoma of the LarynxStage IV Verrucous Carcinoma of the Oral CavityStage IVA Cervical CancerStage IVB Cervical CancerUnspecified Adult Solid Tumor, Protocol SpecificUntreated Metastatic Squamous Neck Cancer With Occult PrimaryMale Breast CancerNCT00030498National Cancer Institute (NCI)75
已完成
2 期
BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLCLung CancerNCT00410059M.D. Anderson Cancer Center59
已完成
2 期
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell CancerNCT00060307National Cancer Institute (NCI)40